JP2011515462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515462A5 JP2011515462A5 JP2011501736A JP2011501736A JP2011515462A5 JP 2011515462 A5 JP2011515462 A5 JP 2011515462A5 JP 2011501736 A JP2011501736 A JP 2011501736A JP 2011501736 A JP2011501736 A JP 2011501736A JP 2011515462 A5 JP2011515462 A5 JP 2011515462A5
- Authority
- JP
- Japan
- Prior art keywords
- difluoromethyl
- morpholinyl
- triazin
- chloroacetyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- -1 cyano, amino Chemical group 0.000 claims 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 claims 1
- SZAXWOHJCJANOJ-UHFFFAOYSA-N 1-[4-[4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-chloroethanone Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=NC(N2CCN(CC2)C(=O)CCl)=N1 SZAXWOHJCJANOJ-UHFFFAOYSA-N 0.000 claims 1
- BLXAMOAYWDXAMQ-UHFFFAOYSA-N 1-[4-[4-(2-aminopyrimidin-5-yl)-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-chloroethanone Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCN(CC2)C(=O)CCl)=NC(C=2C=CN=CC=2)=N1 BLXAMOAYWDXAMQ-UHFFFAOYSA-N 0.000 claims 1
- WGILTLOWHNKIHY-UHFFFAOYSA-N 1-[4-[4-(6-aminopyridin-3-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-chloroethanone Chemical compound C1=NC(N)=CC=C1C1=NC(N2CCOCC2)=NC(N2CCN(CC2)C(=O)CCl)=N1 WGILTLOWHNKIHY-UHFFFAOYSA-N 0.000 claims 1
- XRNNCVZJKZOBFY-UHFFFAOYSA-N 1-[4-[4-(6-aminopyridin-3-yl)-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-chloroethanone Chemical compound C1=NC(N)=CC=C1C1=NC(N2CCN(CC2)C(=O)CCl)=NC(C=2C=CN=CC=2)=N1 XRNNCVZJKZOBFY-UHFFFAOYSA-N 0.000 claims 1
- BLKITOAQWRRBKL-UHFFFAOYSA-N 2,2,2-trichloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)C(Cl)(Cl)Cl)CC1 BLKITOAQWRRBKL-UHFFFAOYSA-N 0.000 claims 1
- VCLOHGYRTQVRPV-UHFFFAOYSA-N 2,2-dichloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)C(Cl)Cl)CC1 VCLOHGYRTQVRPV-UHFFFAOYSA-N 0.000 claims 1
- DTBYHKPKFQPMIR-UHFFFAOYSA-N 2-chloro-1-[3-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-methylamino]azetidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N(C)C2CN(C2)C(=O)CCl)=NC=1N1CCOCC1 DTBYHKPKFQPMIR-UHFFFAOYSA-N 0.000 claims 1
- UIYDDCFSHZHMLI-UHFFFAOYSA-N 2-chloro-1-[3-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino]azetidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1NC1CN(C(=O)CCl)C1 UIYDDCFSHZHMLI-UHFFFAOYSA-N 0.000 claims 1
- UABFLXOFYDMLQA-UHFFFAOYSA-N 2-chloro-1-[4-[4-(1h-indazol-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)CCl)CCN1C1=NC(N2CCOCC2)=NC(C=2C=3C=NNC=3C=CC=2)=N1 UABFLXOFYDMLQA-UHFFFAOYSA-N 0.000 claims 1
- JACRHFNBXLLWGC-UHFFFAOYSA-N 2-chloro-1-[4-[4-(1h-indazol-4-yl)-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)CCl)CCN1C1=NC(C=2C=CN=CC=2)=NC(C=2C=3C=NNC=3C=CC=2)=N1 JACRHFNBXLLWGC-UHFFFAOYSA-N 0.000 claims 1
- QATBQFBTMUNHLA-UHFFFAOYSA-N 2-chloro-1-[4-[4-(3-hydroxyphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound OC1=CC=CC(C=2N=C(N=C(N=2)N2CCOCC2)N2CCN(CC2)C(=O)CCl)=C1 QATBQFBTMUNHLA-UHFFFAOYSA-N 0.000 claims 1
- NTAWEQHYZARGKO-UHFFFAOYSA-N 2-chloro-1-[4-[4-(3-hydroxyphenyl)-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound OC1=CC=CC(C=2N=C(N=C(N=2)N2CCN(CC2)C(=O)CCl)C=2C=CN=CC=2)=C1 NTAWEQHYZARGKO-UHFFFAOYSA-N 0.000 claims 1
- CXXCZJFWDZWVTM-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)CCl)CC1 CXXCZJFWDZWVTM-UHFFFAOYSA-N 0.000 claims 1
- SPADOUNWWMPTEU-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=1)=NC(C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 SPADOUNWWMPTEU-UHFFFAOYSA-N 0.000 claims 1
- RWLWZTIQTOPOJI-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=1)=NC(N2CCN(CC2)C(=O)CCl)=NC=1C1=CC=NC=C1 RWLWZTIQTOPOJI-UHFFFAOYSA-N 0.000 claims 1
- VPXOGZBTJSRFTJ-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)CCl)CC1 VPXOGZBTJSRFTJ-UHFFFAOYSA-N 0.000 claims 1
- ASTLEWBNLRJQNE-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 ASTLEWBNLRJQNE-UHFFFAOYSA-N 0.000 claims 1
- GJKRWQWQISVTQV-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=1)=NC(N2CCN(CC2)C(=O)CCl)=NC=1C1=CC=NC=C1 GJKRWQWQISVTQV-UHFFFAOYSA-N 0.000 claims 1
- IWNARFWONWBMKS-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)CCl)CC1 IWNARFWONWBMKS-UHFFFAOYSA-N 0.000 claims 1
- CMZZOPPGQGMPJV-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]propan-1-one Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)C(C)Cl)CC1 CMZZOPPGQGMPJV-UHFFFAOYSA-N 0.000 claims 1
- JMECLBWPUPUUTM-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 JMECLBWPUPUUTM-UHFFFAOYSA-N 0.000 claims 1
- QMZAEEDKGAKPCW-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCN(CC2)C(=O)CCl)=NC=1C1=CC=NC=C1 QMZAEEDKGAKPCW-UHFFFAOYSA-N 0.000 claims 1
- KHMXRDQDFBYNSH-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)CCl)CC1 KHMXRDQDFBYNSH-UHFFFAOYSA-N 0.000 claims 1
- NEVBIZOZXWSJNB-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 NEVBIZOZXWSJNB-UHFFFAOYSA-N 0.000 claims 1
- IEPGTHZLNFULRN-UHFFFAOYSA-N 2-chloro-1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCN(CC2)C(=O)CCl)=NC=1C1=CC=NC=C1 IEPGTHZLNFULRN-UHFFFAOYSA-N 0.000 claims 1
- IAOWQVXUCSALQR-UHFFFAOYSA-N 2-chloro-1-[4-[4-[3-(hydroxymethyl)phenyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound OCC1=CC=CC(C=2N=C(N=C(N=2)N2CCOCC2)N2CCN(CC2)C(=O)CCl)=C1 IAOWQVXUCSALQR-UHFFFAOYSA-N 0.000 claims 1
- BSAYQQGQUQTDMI-UHFFFAOYSA-N 2-chloro-1-[4-[4-[3-(hydroxymethyl)phenyl]-6-pyridin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone Chemical compound OCC1=CC=CC(C=2N=C(N=C(N=2)N2CCN(CC2)C(=O)CCl)C=2C=CN=CC=2)=C1 BSAYQQGQUQTDMI-UHFFFAOYSA-N 0.000 claims 1
- HZRNSPCMNNVYDW-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-[3-(dimethylamino)propoxy]benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-methylamino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCCCN(C)C)=CC=CC=2N1C(N=1)=NC(N(C)C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 HZRNSPCMNNVYDW-UHFFFAOYSA-N 0.000 claims 1
- BJAYOLPEZVHSLS-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-[3-(dimethylamino)propoxy]benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCCCN(C)C)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1OC1CCN(C(=O)CCl)CC1 BJAYOLPEZVHSLS-UHFFFAOYSA-N 0.000 claims 1
- NNTHRMICRYVDHU-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1NC1CCN(C(=O)CCl)CC1 NNTHRMICRYVDHU-UHFFFAOYSA-N 0.000 claims 1
- LRCBDVDTAQXAGK-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1OC1CCN(C(=O)CCl)CC1 LRCBDVDTAQXAGK-UHFFFAOYSA-N 0.000 claims 1
- HYXCVABMVKHIFU-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-ethoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]sulfanyl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OCC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1SC1CCN(C(=O)CCl)CC1 HYXCVABMVKHIFU-UHFFFAOYSA-N 0.000 claims 1
- YUYDCDNKFLONHQ-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1NC1CCN(C(=O)CCl)CC1 YUYDCDNKFLONHQ-UHFFFAOYSA-N 0.000 claims 1
- MWNAUJJGVXRPSG-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1OC1CCN(C(=O)CCl)CC1 MWNAUJJGVXRPSG-UHFFFAOYSA-N 0.000 claims 1
- GVYXSNQIENQZFV-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-hydroxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]sulfanyl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(O)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1SC1CCN(C(=O)CCl)CC1 GVYXSNQIENQZFV-UHFFFAOYSA-N 0.000 claims 1
- CSICSMWCXFHVKK-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-methylamino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N(C)C2CCN(CC2)C(=O)CCl)=NC=1N1CCOCC1 CSICSMWCXFHVKK-UHFFFAOYSA-N 0.000 claims 1
- YNQOFUZDWZHACO-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1NC1CCN(C(=O)CCl)CC1 YNQOFUZDWZHACO-UHFFFAOYSA-N 0.000 claims 1
- FSUBAMNDPWSDIV-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1OC1CCN(C(=O)CCl)CC1 FSUBAMNDPWSDIV-UHFFFAOYSA-N 0.000 claims 1
- QRVYVXUHSGIUEZ-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]sulfanyl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=C(N=1)N2CCOCC2)=NC=1SC1CCN(C(=O)CCl)CC1 QRVYVXUHSGIUEZ-UHFFFAOYSA-N 0.000 claims 1
- MNCSXHRJHLLTRA-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=C(N=1)N2CCOCC2)=NC=1NC1CCN(C(=O)CCl)CC1 MNCSXHRJHLLTRA-UHFFFAOYSA-N 0.000 claims 1
- IJGYXSYURNITFC-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=C(N=1)N2CCOCC2)=NC=1OC1CCN(C(=O)CCl)CC1 IJGYXSYURNITFC-UHFFFAOYSA-N 0.000 claims 1
- UFLKYTBJELJXNA-UHFFFAOYSA-N 2-chloro-1-[4-[[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]sulfanyl]piperidin-1-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=C(N=1)N2CCOCC2)=NC=1SC1CCN(C(=O)CCl)CC1 UFLKYTBJELJXNA-UHFFFAOYSA-N 0.000 claims 1
- WFGXGZFUBZKGDT-UHFFFAOYSA-N 2-chloro-n-[1-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]azetidin-3-yl]-n-methylacetamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CC(C2)N(C)C(=O)CCl)=NC=1N1CCOCC1 WFGXGZFUBZKGDT-UHFFFAOYSA-N 0.000 claims 1
- FJILIOHMVAFTDV-UHFFFAOYSA-N 2-chloro-n-[1-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperidin-4-yl]-n-methylacetamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCC(N(C)C(=O)CCl)CC1 FJILIOHMVAFTDV-UHFFFAOYSA-N 0.000 claims 1
- DXXWJNJCSUHILR-UHFFFAOYSA-N 3-[1-[4-[4-(chloromethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2-(difluoromethyl)benzimidazol-4-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound FC(F)C1=NC=2C(OCCCN(C)C)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(S(=O)(=O)CCl)CC1 DXXWJNJCSUHILR-UHFFFAOYSA-N 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- ZQTSFAONGDKHCD-UHFFFAOYSA-N 4-[1-[1-(chloromethylsulfonyl)piperidin-4-yl]-6-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=C1N(C2CCN(CC2)S(=O)(=O)CCl)N=CC1=1)=NC=1N1CCOCC1 ZQTSFAONGDKHCD-UHFFFAOYSA-N 0.000 claims 1
- AILLDYHYJOFYDK-UHFFFAOYSA-N 4-[2-[4-(chloromethylsulfonyl)piperazin-1-yl]-6-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]pyrimidin-4-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=CC(N2CCOCC2)=NC=1N1CCN(S(=O)(=O)CCl)CC1 AILLDYHYJOFYDK-UHFFFAOYSA-N 0.000 claims 1
- WYCPOEIUUCAPMV-UHFFFAOYSA-N 4-[4-[4-(bromomethylsulfonyl)piperazin-1-yl]-6-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(S(=O)(=O)CBr)CC1 WYCPOEIUUCAPMV-UHFFFAOYSA-N 0.000 claims 1
- FSFGWLJCEFUATQ-UHFFFAOYSA-N 4-[4-[4-(chloromethylsulfonyl)piperazin-1-yl]-6-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(S(=O)(=O)CCl)CC1 FSFGWLJCEFUATQ-UHFFFAOYSA-N 0.000 claims 1
- DDGXHRREFJTKDQ-UHFFFAOYSA-N 4-[4-[4-(chloromethylsulfonyl)piperazin-1-yl]-6-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]pyrimidin-2-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=CC(N2CCN(CC2)S(=O)(=O)CCl)=NC=1N1CCOCC1 DDGXHRREFJTKDQ-UHFFFAOYSA-N 0.000 claims 1
- HJGPEOFMUDMIRJ-UHFFFAOYSA-N 4-[6-[4-(chloromethylsulfonyl)piperazin-1-yl]-2-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]pyrimidin-4-yl]morpholine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=CC=1N1CCN(S(=O)(=O)CCl)CC1 HJGPEOFMUDMIRJ-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- UPCVEYWTLBPVMH-UHFFFAOYSA-N [2-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]-2-oxoethyl] methanesulfonate Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCN(C(=O)COS(C)(=O)=O)CC1 UPCVEYWTLBPVMH-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- IHAVJVYHVXTMCI-UHFFFAOYSA-N n-[1-(chloromethylsulfonyl)piperidin-4-yl]-4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-n-methyl-6-morpholin-4-yl-1,3,5-triazin-2-amine Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N(C)C2CCN(CC2)S(=O)(=O)CCl)=NC=1N1CCOCC1 IHAVJVYHVXTMCI-UHFFFAOYSA-N 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4006408P | 2008-03-27 | 2008-03-27 | |
| US61/040,064 | 2008-03-27 | ||
| PCT/NZ2009/000038 WO2009120094A2 (en) | 2008-03-27 | 2009-03-26 | Substituted pyrimidines and triazines and their use in cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515462A JP2011515462A (ja) | 2011-05-19 |
| JP2011515462A5 true JP2011515462A5 (cg-RX-API-DMAC10.html) | 2012-05-17 |
Family
ID=40810252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501736A Abandoned JP2011515462A (ja) | 2008-03-27 | 2009-03-26 | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110053907A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2276750A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2011515462A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009120094A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2683805C (en) | 2007-04-13 | 2014-09-23 | The Regents Of The University Of Michigan | Systems and methods for tissue imaging |
| CA2716940C (en) * | 2008-02-29 | 2016-01-19 | The Regents Of The University Of Michigan | Systems and methods for imaging changes in tissue |
| JPWO2010092962A1 (ja) * | 2009-02-12 | 2012-08-16 | アステラス製薬株式会社 | へテロ環誘導体 |
| EP2408773A2 (en) | 2009-03-20 | 2012-01-25 | Amgen, Inc | Inhibitors of pi3 kinase |
| US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| WO2010110686A1 (en) * | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| EP2532659A1 (en) | 2009-07-07 | 2012-12-12 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| EP2483272A4 (en) * | 2009-09-29 | 2013-09-18 | Xcovery Holding Co Llc | SELECTIVE PI3K (DELTA) INHIBITOR |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| RS56432B1 (sr) | 2009-11-05 | 2018-01-31 | Rhizen Pharmaceuticals S A | Novi benzopiran modulatori kinaze |
| GB201007227D0 (en) * | 2010-04-30 | 2010-06-16 | Univ Basel | Piperazinotriazines |
| EA023931B1 (ru) | 2010-08-10 | 2016-07-29 | Астеллас Фарма Инк. | Гетероциклическое соединение |
| WO2012044641A1 (en) | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| BR112013024907A2 (pt) | 2011-03-28 | 2016-12-20 | Mei Pharma Inc | composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k |
| MX365160B (es) | 2011-05-04 | 2019-05-24 | Rhizen Pharmaceuticals Sa | Compuestos novedosos como moduladores de proteína cinasas. |
| WO2013003826A1 (en) | 2011-06-29 | 2013-01-03 | The Regents Of The University Of Michigan | Analysis of temporal changes in registered tomographic images |
| GEP20166432B (en) | 2011-09-27 | 2016-02-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2013052395A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
| US9053534B2 (en) | 2011-11-23 | 2015-06-09 | The Regents Of The University Of Michigan | Voxel-based approach for disease detection and evolution |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| WO2013166416A1 (en) | 2012-05-04 | 2013-11-07 | The Regents Of The University Of Michigan | Mean diffusivity measurement corrections for gradient non-linearity |
| SG11201408821SA (en) | 2012-07-04 | 2015-01-29 | Rhizen Pharmaceuticals Sa | Selective pi3k delta inhibitors |
| WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CA2901613C (en) | 2013-03-13 | 2020-10-20 | The Regents Of The University Of Michigan | Dual mek/pi3k inhibitors and therapeutic methods using the same |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| US10650512B2 (en) | 2016-06-14 | 2020-05-12 | The Regents Of The University Of Michigan | Systems and methods for topographical characterization of medical image data |
| EP3481822B1 (en) | 2016-07-06 | 2022-06-22 | The Regents of The University of Michigan | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
| MY195123A (en) | 2017-01-23 | 2023-01-11 | Cadent Therapeutics Inc | Potassium Channel Modulators |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| WO2019032640A1 (en) | 2017-08-11 | 2019-02-14 | The Regents Of The University Of Michigan | MEK / P13K, JAK / MEK, JAK / P13K / MTOR AND MEK / P13K / MTOR BIKE INHIBITORS AND METHODS FOR ENHANCING LYMPHATIC ABSORPTION, BIOAVAILABILITY AND SOLUBILITY OF THERAPEUTIC COMPOUNDS |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
| WO2019119206A1 (en) * | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| US11993586B2 (en) | 2018-10-22 | 2024-05-28 | Novartis Ag | Crystalline forms of potassium channel modulators |
| CN113004246B (zh) * | 2021-02-22 | 2022-02-01 | 广西医科大学 | 1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途 |
| US20240217960A1 (en) * | 2021-04-09 | 2024-07-04 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| CN117751127A (zh) * | 2021-08-20 | 2024-03-22 | 南京大美生物制药有限公司 | 一种五元含氮杂环并杂芳基类衍生物及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1222049B (it) * | 1987-07-16 | 1990-08-31 | Ciba Geygi Spa | Composti piperidin triazinici utilizzabili come stabilizzanti per polimeri sintetici |
| US5244948A (en) * | 1988-06-30 | 1993-09-14 | Ciba-Geigy Corporation | Process for the stabilization of polyolefins |
| US5306495A (en) * | 1988-08-04 | 1994-04-26 | Ciba-Geigy Corporation | Compounds containing substituted piperidine groups for use as stabilizers for organic materials |
| IT1237126B (it) * | 1989-11-07 | 1993-05-18 | Ciba Geigy Spa | Stabilizzanti polimerici contenenti gruppi amminici impediti e gruppi idrossilamminici |
| US5258138A (en) * | 1990-07-20 | 1993-11-02 | Ciba-Geigy Corporation | Process for stabilizing ethylenically unsaturated compounds and stabilized monomer compositions |
| TW224983B (cg-RX-API-DMAC10.html) * | 1991-08-28 | 1994-06-11 | Hoechst Ag | |
| AU665238B2 (en) * | 1992-02-28 | 1995-12-21 | Zenyaku Kogyo Kabushiki Kaisha | S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient |
| HU209678B (en) * | 1992-06-09 | 1994-10-28 | Richter Gedeon Vegyeszet | Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them |
| IT1263993B (it) * | 1993-04-05 | 1996-09-06 | Ciba Geigy Spa | Composti piperidin-triazinici atti all'impiego come stabilizzanti per materiali organici |
| IT1270975B (it) * | 1993-06-03 | 1997-05-26 | Ciba Geigy Spa | Composti piperidin-triazinici atti all'impiego come stabilizzanti allaluce, al calore e alla ossidazione per materiali organici |
| DE59505941D1 (de) * | 1994-01-19 | 1999-06-24 | Ciba Geigy Ag | Stabilisieren von Leder gegen thermische und photochemische Zersetzung |
| EP0707035B1 (de) * | 1994-10-12 | 1999-01-13 | Ciba SC Holding AG | HALS-Phosphorinane als Stabilisatoren |
| EP0711804A3 (de) * | 1994-11-14 | 1999-09-22 | Ciba SC Holding AG | Kryptolichtschutzmittel |
| DE19522137A1 (de) * | 1995-06-19 | 1997-01-02 | Hoechst Schering Agrevo Gmbh | 2-Amino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| JP3512911B2 (ja) * | 1995-07-11 | 2004-03-31 | 富士写真フイルム株式会社 | 紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法 |
| US6046304A (en) * | 1995-12-04 | 2000-04-04 | Ciba Specialty Chemicals Corporation | Block oligomers containing 2,2,6,6-tetramethyl-4-piperidyl groups as stabilizers for organic materials |
| US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| KR100563514B1 (ko) * | 1997-07-24 | 2006-03-27 | 젠야쿠코교가부시키가이샤 | 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제 |
| JPH11174638A (ja) * | 1997-12-08 | 1999-07-02 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| US6150362A (en) * | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| US5990208A (en) * | 1997-12-15 | 1999-11-23 | Ciba Specialty Chemicals Corporation | Stabilization of polycarbonate/ABS blends with mixtures of hindered amines and UV absorbers |
| EP1140100A2 (en) * | 1999-01-13 | 2001-10-10 | Biomes, Inc. | Use of (s)-triazines for treating apicomplexan parasitic infections |
| EP1183245B1 (en) * | 1999-04-22 | 2007-05-09 | H. Lundbeck A/S | Selective npy (y5) antagonists |
| WO2002006271A1 (en) * | 2000-07-19 | 2002-01-24 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives |
| US6465645B1 (en) * | 2001-04-17 | 2002-10-15 | Ciba Specialty Chemicals Corporation | Long chain hindered amines and compositions stabilized therewith |
| CA2445395C (en) * | 2001-04-27 | 2010-03-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
| AU2003275630B2 (en) * | 2002-10-25 | 2010-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent comprising the same as effective component |
| WO2005028467A1 (en) * | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| WO2005095389A1 (ja) * | 2004-03-31 | 2005-10-13 | Zenyaku Kogyo Kabushiki Kaisha | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
| AU2005317176A1 (en) * | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| US20080132509A1 (en) * | 2004-12-13 | 2008-06-05 | Neurogen Corporation | Substituted Biaryl Analogues |
| GB0503962D0 (en) * | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
| EP1864665B1 (en) * | 2005-03-11 | 2012-05-16 | Zenyaku Kogyo Kabushikikaisha | Immunosuppressive agent comprising a heterocyclic compound as active ingredient |
| EP1931674B1 (en) * | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070244110A1 (en) * | 2006-04-14 | 2007-10-18 | Zenyaku Kogyo Kabushiki Kaisha | Treatment of prostate cancer, melanoma or hepatic cancer |
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| CN101535296A (zh) * | 2006-09-14 | 2009-09-16 | 阿斯利康(瑞典)有限公司 | 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物 |
| CN101563339A (zh) * | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物 |
| EP2057147A1 (en) * | 2006-09-14 | 2009-05-13 | Astra Zeneca AB | Pyrimidine derivatives |
| EP2064203A1 (en) * | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008072850A1 (en) * | 2006-12-11 | 2008-06-19 | Amorepacific Corporation | Triazine derivatives having inhibitory activity against acetyl-coa carboxylase |
| JP2011510010A (ja) * | 2008-01-15 | 2011-03-31 | ワイス・エルエルシー | ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成 |
| US20090192176A1 (en) * | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
-
2009
- 2009-03-26 US US12/934,616 patent/US20110053907A1/en not_active Abandoned
- 2009-03-26 EP EP09724191A patent/EP2276750A2/en not_active Withdrawn
- 2009-03-26 WO PCT/NZ2009/000038 patent/WO2009120094A2/en not_active Ceased
- 2009-03-26 JP JP2011501736A patent/JP2011515462A/ja not_active Abandoned